Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis

NCT05239468 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.

NCT NCT05239468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05239468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
Lead sponsor
Intercept Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 21, 2022
Completion date
September 1, 2025
Enrollment
72 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis